1. This multi-year, open-label extension of phase 2 trials examining the LDL-lowering efficacy of evolocumab (PCSK9-inhibitor) showed that evolocumab plus ...
1. This prospective cohort study, conducted in Copenhagen, found that mild-to-moderate levels of non-fasting hypertriglyceridemia, from 177 mg/dL (2 mmol/L) ...
![Adverse pregnancy outcomes associated with thrombophilias [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2015/07/Classics-2-Minute-Medicine-e1436017941513-350x250.png)
1. In the 1970s, observational data suggested a direct link between serum cholesterol levels and the risk of coronary heart ...
1. Presence of a familial hypercholesterolemia mutation without elevated total cholesterol levels is insufficient to make diagnosis of familial hypercholesterolemia. ...
1. LDL-C-lowering alleles at the NPC1L1 locus are directly associated with an increased risk of type 2 diabetes, but a ...
1. Medications that lower low-density lipoprotein cholesterol levels, including statins and non-statins alike, provided similarly reduced risks of major vascular ...
1. For patients with atherosclerotic cardiovascular disease, PCSK9 inhibitors, either in monotherapy for statin-intolerant patients or in addition to statin ...
1. Among patients with muscle-related statin intolerance, evolocumab reduced LDL-C levels significantly more than ezetimibe. 2. Evolocumab and ezetimibe had ...
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction Few medications have been shown to improve mortality or quality of ...
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Herpes zoster continues to be a menacing disease especially ...
